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ABSTRACT
Introduction: We examined patient outcomes after Gamma Knife stereotactic radiosurgery (GKSRS) 
salvage therapy for recurrent high-grade gliomas (HGGs) to determine whether tumor grade or 
lesion size affected overall survival (OS) and progression-free survival (PFS).
Methods: This single-center retrospective study assessed radiographic response and clinical 
outcomes following GKSRS salvage treatment of recurrent malignant gliomas (January 2005–
March 2014).
Results: A total of 121 patients (67 female) with 132 tumors were treated. Median (range) PFS was 
4.7 (3.9-5.4) months for the cohort, 6.8 (4.6-8.9) months for initial grade 2 tumors, 4.2 (1.9-6.5) 
months for initial grade 3 tumors, and 4.3 (3.7-4.9) months for initial grade 4 tumors. Patients with 
small lesions (≤6.7 cm3; n = 53) had significantly longer median (range) PFS (6.8 [4.8-8.8], P=0.02).
Conclusions: GKSRS offers meaningful salvage therapy with minimal morbidity in appropriately 
selected patients with focally recurrent HGGs.
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INTRODUCTION
Glioblastoma (GBM) accounts for approximately 15% 
of all brain tumors.(1) Because GBMs are highly infiltra-
tive and relatively resistant to radiation and chemotherapy, 
most patients with GBM experience a recurrence within 1 
year. It is considered rare for patients to survive more than 
5 years after diagnosis, although reports of long-term sur-
vivors have been published.(2) The most recent advance is 
the addition of tumor-treating fields (TTF), with a reported 
20.9-month median overall survival for a cohort of 466 
patients treated with upfront TTF in addition to standard 
resection or biopsy plus radiation and temozolomide.(3) 
However, even in the best-reported results to date in this 
large study of 695 patients, the median progression-free 
survival (PFS) was still only 6.7 months.(3)
Stereotactic radiosurgery delivered by the Gamma 
Knife (Elekta, AB, Stockholm, Sweden) (GKSRS) or 
other specialized treatment units offers the ability to 
treat relatively deep, small areas of focally recurrent 
high-grade glioma (HGG) in a single-day outpatient 
setting through a non-surgically invasive approach with 
a low risk of causing further deficits in the short term. 
However, this technique has been criticized for its ina-
bility to treat the infiltrative nature of HGG and for the 
risk of post-radiation treatment effect (PRTE).
This study sought to add to the current body of 
knowledge regarding the outcomes of patients treated 
with GKSRS as salvage therapy for recurrent HGG 
to help physicians best determine when GKSRS is 
an appropriate treatment option. We hypothesized 
that overall survival (OS) and PFS would decrease as 
tumor grade increased and that both OS and PFS would 
decrease as lesion size increased.
MATERIAL AND METHODS
A single-center retrospective study was conducted 
evaluating radiographic response and clinical outcomes 
after GKSRS was administered to patients with recur-
rent gliomas. The institutional review board approved the 
study and waived informed consent requirements. Data 
were collected from hospital and medical office records, 
and all available treatment and surveillance magnetic reso-
nance images were reviewed as described below.
Inclusion Criteria
All adult patients treated with GKSRS for recurrent glio-
mas between January 1, 2005, and March 31, 2014, were 
evaluated for inclusion. Patients with initial World Health 
Organization (WHO) grade 1 tumors were excluded. 
Patients with WHO grade 2, 3, and 4 gliomas were included 
based on initial pathologic tissue diagnosis regardless 
of the time between diagnosis and salvage GKSRS. No 
patients had GKSRS as a primary treatment. A biopsy was 
not required before salvage treatment. However, during a 
weekly review board meeting before patient treatment, a 
consensus opinion was reached by a neurosurgeon, radia-
tion oncologist, and neuroradiologist that a patient’s radio-
graphic change was consistent with focal tumor progression 
or malignant degeneration of prior lower-grade tumors and 
was not consistent with PRTE. No patients with diffusely 
infiltrative or nonenhancing tumors were treated in this 
series. Previous grade 2 tumors were included because the 
recurrences were felt to be of high grade due to the presence 
of enhancing nodules in previously nonenhancing tumors.
Study Population and Treatment Technique
The decision to treat patients was made on an 
individual basis and is reported in a retrospective 
fashion. Per our institutional protocol, all cases 
suspected to be recurrent HGG were presented and 
reviewed in a multidisciplinary radiosurgical confer-
ence/tumor board before treatment to gain consen-
sus approval for the appropriateness and safety of 
GKSRS as a salvage therapy. It is important to note 
that multiple options for therapy, including enroll-
ment in clinical trials, were typically discussed and 
were chosen many times by patients not included 
in this study. Additionally, several patients in this 
study had not responded to therapy after enrollment 
in various clinical trials, and GKSRS was chosen as 
their salvage treatment.
All patients were treated with the Leksell Gamma Knife 
model C (Elekta, Stockholm, Sweden) prior to 2007 and 
with the Perfexion model (Elekta) thereafter. T-1 weighted 
SPGR gadolinium-enhanced MR images with 1-mm con-
tiguous slices were obtained. The volume of the enhancing 
nodule was outlined for treatment using the GammaPlan 
(Elekta) software. The percentage of the target volume 
coverage was calculated in all cases with 100% coverage 
by the 50% isodose line achieved in nearly all cases. Typi-
cally, a generous coverage of the target beyond the enhanc-
ing margin was performed when the location was deemed 
appropriate; however, an intentional, specific additional 
margin beyond the edge of enhancement, as reported in 
some other series, was not specifically prescribed.(4) The 
mean and standard deviation for coverage beyond the mar-
gin, calculated by subtracting the target volume (mL) from 
the treatment isodose line volume (mL), was 4.33 ± 6.63 
mL. The dose at the 50% isodose line was 12-15 Gy, lower 
than in other reported series and lower than typically pre-
scribed for metastatic disease, with the goal of avoiding 
PRTE as all patients had received prior high-dose inten-
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sity-modulated radiation therapy (IMRT) near the area of 
salvage GKSRS.
Overall Survival and Progression-Free Survival 
Analyses
To retrospectively differentiate tumor progression from 
PRTE, we applied the Response Assessment in Neuro-
oncology (RANO) criteria based on radiographic presenta-
tion. Disease progression was defined as greater than a 25% 
increase in T1-enhanced lesion volume. Progression was 
then subclassified as either in-field (within 50% isodose 
margin), marginal (within 2 cm of 50% isodose margin), 
or distant (greater than 2 cm away from 50% isodose line). 
For classification as progressive disease, in-field and mar-
ginal disease progression criteria must have been met for 
a minimum of 4 successive imaging dates. If progression 
was maintained, the first date on which progression was 
observed was established as the start date of progressive 
disease. If 4 successive scans did not meet this requirement, 
no date for progressive disease was assigned. However, if 
distant disease progression was established at any point in 
follow-up, the first date at which progression occurred was 
determined to be the date of progressive disease. When 
perfusion MRIs were available, focally increased rela-
tive cerebral blood volume corresponding to the region of 
enhancement was confirmatory for progressive disease, 
and low relative cerebral blood volume was deemed con-
sistent with PRTE. If no imaging follow-up was available, 
the halfway point between last follow-up and date of death 
was used to estimate the date of disease progression.
Survival analyses were conducted for OS using the 
date of death minus the date of initial resection. OS was 
also computed using the date of death minus date of first 
GKSRS. PFS was computed using the date of progres-
sion minus date of first GKSRS. Kaplan-Meier curves are 
shown by initial tumor grade and by lesion size. Lesion 
size was addressed as both a continuous and dichoto-
mized variable using median value to large tumors (above 
median) and small tumors (at or below median). For 
patients with multiple lesions, the largest lesion size was 
used to determine the patient’s tumor-size category.
Karnofsky Performance Status
The Karnofsky Performance Status (KPS) score, a 
physician-assigned value, was used to evaluate patient 
KPS. The KPS scale provides a score of 0–100 in 
10-point intervals, each based on specific criteria, such 
as the ability to work, care for oneself, and degree of 
symptoms. A score of zero reflects a deceased patient, 
and a score of 100 reflects no evidence of disease and 
normal functional capacity.
Statistical Analysis
Our cohort is described using counts with percent-
ages and means with standard deviations. Kaplan-Meier 
analyses were used to estimate OS from initial resection 
and OS and PFS from the time of GKSRS for the entire 
cohort, by WHO tumor grade, and by lesion volume split 
at the median to represent large (>6.7 cm3) versus small 
(≤6.7 cm3) tumors. The number of events (deaths), cen-
sored cases, and patients exposed to risk at each interval 
are reported. Mean and median survival estimates are 
reported with standard errors and 95% confidence inter-
vals. Although standard median survival statistics are 
reported, we also provide mean survival as an additional 
statistic to describe patient trajectory. Pairwise log-rank 
tests were used to assess for statistically significant dif-
ferences between survival estimates. KPS value differ-
ences were compared using a repeated-measures general 
linear model with follow-up visit as the within-subjects 
factor and KPS score as the dependent variable. P values 
<0.05 were considered statistically significant. SPSS ver-
sion 22 was used for analyses.
RESULTS
Our cohort consisted of 121 patients with 132 
tumors who underwent GKSRS for recurrent glio-
mas. The mean patient age was 49.2±15.7 years, 
and 67 of 121 (55.4%) were female. Initial tumor 
grade was missing for 2 patients (Table 1). For the 
remaining 119 patients, the initial tumor grade for 
the majority was grade 4 (n=73, 61.3%), followed by 
grade 3 (n= 27, 22.7%) and grade 2 (n=19, 16.0%). 
Prior to GKSRS, 100% (n=121) of patients under-
went resection, 71.1% (n=86) underwent re-resec-
tion, 91.7% (n=111) underwent IMRT, 14.0% (n=17) 
were treated with carmustine implants, 21.5% (n=26) 
were participants in a clinical trial, and 28.9% (n=35) 
were administered BVZ.
Survival and Tumor Grade
Overall Survival after Initial Resection
Survival estimates for the combined cohort and 
separated by tumor grade are reported in Table 2. 
The median OS of the combined cohort was 26.0 
(95% CI, 18.1-33.9) months and 86.0 (range 39.6-
132.4) months for patients with prior grade 2 tumors, 
33.0 (range 26.2-40.3) months for grade 3, and 20.5 
(range 17.5-23.5) months for grade 4. Patients with 
small lesions (≤6.7 cm3) had significantly longer OS 
with a median OS of 32.3 (range 25.2–39.5) months 
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compared to 21.4 (range 17.1–25.8) months for 
patients with large lesions (>6.7 cm3) (P=0.04). The 
overall log-rank test and all pairwise comparisons 
were statistically significant at P<0.001, suggesting 
a significant decrease in survival with each increase 
in tumor grade. Kaplan-Meier curves reported by 
tumor grade are shown in Figure 1A.
Overall Survival after GKSRS
The median OS calculated from the date of GKSRS 
for all tumor grades combined was 8.6 (range 6.9-10.4) 
months. OS was 12.7 (range 7.8-17.5) months for the 
prior grade 2 cohort, 9.7 (range 5.9-13.4) months for 
the grade 3 cohort, and 8.2 (range 6.3-10.1) months for 
the grade 4 cohort. The overall log-rank test resulted 
in P=0.07, and pairwise comparisons demonstrated a 
significantly longer survival for the grade 2 cohort in 
comparison to the grade 4 cohort (P=0.04) (Figure 1B).
Progression-Free Survival after GKSRS
Date of progression was documented for 57 patients 
and calculated as described in Methods for the remaining 
62 patients. Median PFS was 4.7 (range 3.9-5.4) months 
for the combined cohort, 6.8 (range 4.6-8.9) months 
for prior grade 2 patients, 4.2 (range 1.9-6.5) months 
for grade 3 patients, and 4.3 (range 3.7-4.9) months for 
grade 4 patients. PFS was not significantly different by 
tumor grade (P=0.20) (Figure 1C). Additional analysis 
using target volume as a continuous variable and adjust-
ing for age, sex, initial KPS, multiple lesions, and initial 
tumor grade failed to demonstrate a significant difference 
in PFS (P=0.14). Multiple lesions were found to be the 
sole significant co-variable in the model (P=0.04). We 
were able to review imaging data on 81 of the patients 
who had progression. Of these, 44 (54.3%) were classi-
fied as having marginal progression and 37 (45.7%) were 
classified as having distant progression.
Survival and Lesion Size
Survival analyses were also conducted to compare 
the association between lesion size and survival. Data 
on lesion size were missing for 10 patients, resulting 
in a sample size of 111, as reflected in Table 2. Patients 
with small lesions had significantly longer OS, with a 
median OS of 32.3 (range 25.2-39.5) months compared 
to 21.4 (range 17.1-25.8) months for patients with 
large lesions (P=0.04). Patients with small lesions also 
had a longer OS after GKSRS, with a median of 13.0 
(range 8.0-18.0) months compared to 7.4 (range 5.1-
9.6) months for patients with large lesions (P=0.046). 
Additionally, patients with small lesions had a longer 
PFS after GKSRS, with a median of 6.8 (range 4.8-8.8) 
months for those with small lesions versus 4.2 (range 
3.5-5.0) months for those with large lesions (P=0.02). 
Kaplan-Meier curves comparing survival by size and 
grade are shown in Figure 2.
Progression-Free Survival and Tumor Grade and 
Lesion Size
Given the general association between increased 
lesion size and decreased PFS after GKSRS and the 
lack of association between PFS and tumor grade, we 
explored tumor grade and lesion size within a single 
PFS analysis (Table 2 and Figure 2). The overall log-
Table 1. Characteristics of cohort of 121 patients with 
132 glioblastomas
Variable No. (%)*
Age, mean±SD, yr 49.2±15.7
Sex
Male 54 (44.6%)
Female 67 (55.4%)
Initial WHO tumor grade 
(n=119 patients)† 
2 19 (16.0%)
3 27 (22.7%)
4 73 (61.3%)
Location (n=132 
tumors)‡
Frontal 41 (31.1%)
Temporal 24 (18.2%)
Parietal 17 (12.9%)
Cerebellum 8 (6.1%)
Occipital 6 (4.5%)
Corpus callosum 6 (4.5%)
Insula 5 (3.8%)
Pons 4 (3.0%)
Thalamus 3 (2.3%)
Medulla 1 (0.8%)
Atrium 1 (0.8%)
Not available/unknown 16 (12.1%)
*Values are number (percentage) unless otherwise indicated.
†Data on WHO tumor grade were missing for 2 patients.
‡Percentages total >100% due to rounding.
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rank test was significant, suggesting significant differ-
ences in PFS after GKSRS by categories combining 
tumor grade and lesion size (P=0.03). Within each 
tumor grade, both mean and median PFS decreased 
when comparing patients with small tumors to those 
with large tumors. Pairwise comparisons reflected 
significantly shorter survival for patients with grade 3 
large tumors versus grade 3 small (P=0.005) and grade 
2 small (P=0.02). Patients with grade 4 large tumors 
also had significantly shorter PFS than those with grade 
3 small tumors (P=0.02). In Figure 2, for significant val-
ues described above, refer to the black dotted survival 
curve for grade 3 large tumors and black solid curve for 
grade 4 large tumors.
Karnofsky Performance Status
Mean KPS values are shown in Table 3 for patients 
before the first GKSRS treatment (initial KPS), the 
first follow-up visit (mean 1.9±1.0 months), and third 
follow-up visit (mean 5.3±2.0 months). The repeated 
measures analysis demonstrated a significant effect 
of time (P<0.001) with all pairwise comparisons sig-
nificant at P<0.001 indicating a significant mean drop 
from initial KPS to KPS at the date of GKSRS treat-
ment and a significant drop from GKSRS treatment to 
first follow-up. Initial KPS was reported for 86 of 121 
patients (71%).
Post-GKSRS Adverse Effects
A total of 29 (24%) of the 121 patients had PRTE 
at any point following GKSRS salvage treatment as 
reported by 2 neuroradiologists. Only 2 (1.7%) patients 
had cerebral edema, and 90 (74.4%) patients had no 
adverse treatment effect.
DISCUSSION
The prognosis for patients with recurrent disease is 
even more dismal than that for patients with newly diag-
nosed disease, prompting the question of whether any 
salvage treatment is justified. Hau et al.(5) addressed 
this question in 2003 and reported a superior median 
PFS rate at 12 months and OS rate at 24 months in 
the reintervention group (71% and 32%, respectively) 
compared with a control group who were not re-treated 
(15% and 5%, respectively). They also reported a sta-
ble or even improved KPS after reintervention in the 
patients selected for treatment. Careful patient selection 
is important for patients to be considered for reinterven-
tion because reports vary widely regarding the benefits 
of salvage therapy.
Ideally, salvage treatments for GBM would have 
a low treatment burden to the patient with a minimal 
recovery time from the treatment because, realistically, 
Table 2. Summary of progression-free survival from time of GKSRS by tumor grade and size
Variable
Grade 2 
Small
Grade 2 
Large
Grade 3 
Small
Grade 3 
Large
Grade 4 
Small
Grade 4 
Large
N 9 9 11 15 33 34
No. of events 8 9 11 13 30 34
No. censored 1 0 0 2 3 0
Mean survival (SE)
[95% CI], months
14.9 (7.0)
[1.3-28.6]
9.3 (4.1)
[1.2-17.4]
13.2 (3.7)
[6.1-20.4]
4.1 (1.0)
[2.1-6.1]
7.6 (1.6)
[4.6-10.7]
5.8 (0.9)
[4.0-7.6]
Median survival (SE)
[95% CI], months
8.1 (0.2)
[7.7-8.5]
4.7 (0.5)
[3.6-5.7]
9.7 (1.4)
[7.0-12.4]
3.6 (0.9)
[1.9-5.3]
4.7 (1.0)
[2.7-6.7]
4.0 (0.6)
[2.9-5.1]
No. patients exposed 
to risk
3 mo 5 3 6 4.5 15 19
6 mo 3.5 1 6 1 7 9
9 mo 2 1 5 6 5
12 mo 1 1 4 2
24 mo 2 1
36 mo 1
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these patients’ life-spans are limited and should not be 
spent in the hospital. Salvage treatment options include 
(1) possible enrollment in clinical trials; (2) re-resection 
with or without a carmustine implant; (3) re-irradiation, 
either after re-resection or as stand-alone salvage treat-
ment with IMRT; (4) brachytherapy seed placement after 
resection; (5) additional chemotherapy; (6) initiation of 
TTF; (7) laser interstitial thermal therapy (LITT); and (8) 
SRS. Each modality exhibits a unique profile of advan-
tages and disadvantages. However, the most efficacious 
treatment course has yet to be elucidated.
The primary objective of this study was to corroborate 
the existing literature regarding the outcomes of patients 
treated with GKSRS as salvage therapy for recurrent 
Figure 1. Kaplan-Meier curves showing survival by 
tumor grade. (A) Overall survival from initial resection. 
(B) Overall survival from time of GKSRS salvage 
therapy. (C) Progression-free survival from time of 
GKSRS salvage therapy. Used with permission of 
Barrow Neurological Institute.
Figure 2. Progression-free survival by tumor grade and 
size after GKSRS. Used with permission of Barrow 
Neurological Institute.
Table 3. Summary of mean Karnofsky Performance 
Status scores over time after GKSRS
Time Point N
Mean value 
(SE)§ 95% CI
Prior to GKSRS 86 87.21 (1.17) 84.92-89.50
First follow-up 
visit*
55 79.27 (1.46) 76.41-82.14
Third follow-up 
visit†
58 67.59 (1.42) 64.80-70.38
*Mean 1.9±1.0 months after first GKSRS salvage treatment.
†Mean 5.3±2.0 months after first GKSRS salvage treatment.
§All pairwise comparisons significant at P<0.001.
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HGG. Several small prospective and retrospective series 
suggest that SRS may provide a survival benefit in recur-
rent HGG, with postirradiation OS ranging from 7 to 
16 months.(2, 6-16) Moreover, 10 additional reports 
between 2005 and 2013 for GKSRS for recurrent GBM 
demonstrated median OS ranging from 9 to 17.9 months 
after salvage SRS, and the median PFS ranged from 4.6 
to 14.9 months.(4, 17-25) Our study, which to our knowl-
edge is the largest series to date, obtained similar results 
with median OS after GKSRS of 8.6 (range 6.9-10.4) 
months and a median PFS of 4.7 (range 3.9-5.4) months. 
These results suggest a meaningful survival benefit to 
patients that is comparable to other salvage treatments. 
For example, a recent series of 37 patients found that 
the median PFS and OS after re-irradiation using IMRT 
without and with BVZ was 5.1 (range 1.6-17.4) months 
and 9.0 (range 6.4-17.8) months, respectively.(26) Chan 
et al.(27) treated 24 patients with recurrent GBM with 
re-resection followed by GliaSite brachytherapy, result-
ing in a median survival time of 9.1 months. Another 
study of permanent brachytherapy showed similar out-
comes with a median OS posttreatment of 10.5 to 12.0 
months.(6) However, significant symptomatic radiation 
toxicity was reported, leading clinicians to disfavor this 
technique.(28)
A challenging factor in treating recurrent GBM is the 
inherent difficulty of differentiating true tumor progres-
sion from pseudoprogression or PRTE using modern 
imaging techniques.(29-31)  In many cases, the patient 
has a mixture of both tumor recurrence and PRTE 
simultaneously. One study found that tumor recurrence 
or a mixture of tumor recurrence and PRTE was twice 
as likely as PRTE alone after radiation therapy for pri-
mary brain gliomas.(32, 33) This confounding variable 
can result in inappropriate treatment because prescrib-
ing any form of additional radiation for patients with 
PRTE results worsens PRTE.
An important distinction should be drawn between 
symptomatic and nonsymptomatic PRTE. Asympto-
matic small areas of necrotic tissue within the margins 
of treatment are in many regards a desired treatment 
response after salvage SRS. It is only considered a 
negative response to treatment when the PRTE extends 
beyond treatment margins with evidence of associated 
symptoms due to edema and mass effect on adjacent 
viable tissue. The incidence of patients experiencing 
symptomatic PRTE following SRS has been reported in 
multiple series, ranging from 6 to 24%, which is simi-
lar to that found in our series (24%).(22, 34-37) Post-
SRS PRTE appears to be relatively less problematic than 
PRTE reported after brachytherapy, likely due to smaller 
overall volumes of treatment.
Inherent limitations of a nonrandomized, retrospec-
tive, single-institution study with a heterogeneous sam-
ple of patients include selection bias. In general, our 
patients were selected for salvage GKSRS when they 
exhibited relatively small areas of nodular tumor recur-
rence, which did not induce significant mass effect that 
would have required surgical resection, or when the 
recurrence was in a deep and relatively difficult location 
for surgical access. Patients with larger tumor burdens 
requiring surgical decompression or with diffuse disease 
and declining clinical status were not chosen for GKSRS 
salvage therapy and were typically referred for hospice 
care. Multifocal nodular disease was not a contraindica-
tion for GKSRS, and its presence may have skewed the 
decision toward salvage GKSRS because multifocal sur-
gical approaches were felt to be contraindicated or exces-
sively burdensome to these patients.
Our retrospective long-term outcome data from a 
large cohort of select patients, with focal nodular areas 
of presumed recurrent disease, suggest that salvage 
GKSRS offers an effective means of adding modest, but 
meaningful, increased survival in these patients with 
minimal treatment burden or recovery time and mini-
mal long-term risk of adverse events. We do not suggest 
that GKSRS is the best or even the first option for these 
patients. We encourage enrollment of these patients into 
well-designed clinical trials, ideally with tissue confir-
mation and molecular profiling-guided targeted thera-
pies in the hope of gaining improved outcomes for these 
and future patients with this disease. However, salvage 
therapy with low-dose, low-volume GKSRS is an 
acceptable treatment option for patients with recurrent 
GBM who are unwilling to undergo invasive surgery or 
enroll in clinical trials of experimental therapies.
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